365 jili
Dexamethasone sodium phosphate SR by Taiwan Liposome for Osteoarthritis Pain: Likelihood of ApprovalUrban Outfitters, Inc. URBN shares traded higher on Wednesday following the release of the company’s third-quarter earnings report, which exceeded expectations. Here’s what you need to know. What To Know: Urban Outfitters reported third-quarter earnings per share of $1.10, beating estimates of 89 cents. Revenue came in at $1.36 billion, up 6.3% year-over-year and ahead of the consensus estimate of $1.32 billion. The company posted net income of $102.9 million for the quarter, compared to $83 million a year ago. Retail net sales rose 3.2%, with comparable retail sales up 1.5%. Anthropologie and Free People brands reported comparable sales growth of 5.8% and 5.3%, respectively, while Urban Outfitters brand sales fell 8.9%. See More: These Analysts Increase Their Forecasts On Urban Outfitters After Q3 Results Nuuly, the company's subscription rental service, grew sales by 48.4%, supported by a 51% increase in active subscribers. Wholesale revenue increased 17.4%, driven by a 20.3% rise in Free People wholesale sales, partially offset by declining Urban Outfitters wholesale revenue. Gross profit for the quarter rose 9.4% to $497.3 million, with a 105-basis-point improvement in gross margin due to higher merchandise markups and fewer markdowns at Urban Outfitters. Operating expenses increased 6.7%, reflecting higher marketing and store payroll costs. “These results were driven by outperformance across all three business segments – Retail, Subscription and Wholesale. Additionally, we’re optimistic about the outlook for Holiday demand and believe total comparable sales could be similar to our third quarter results,” said Richard Hayne , CEO of Urban Outfitters. The company ended the quarter with $182.5 million in cash, $340.4 million in marketable securities and a 10% inventory increase, largely due to early holiday merchandise shipments and higher sales expectations. Following the print, several analysts raised price targets, which appears to have helped push shares higher on Wednesday. Citigroup analyst Paul Lejuez upgraded Urban Outfitters from Neutral to Buy and raised the price target from $42 to $59. Telsey Advisory Group analyst Dana Telsey maintained a Market Perform and raised the price target from $44 to $46. BofA Securities analyst Lorraine Hutchinson maintained a Buy and raised the price target from $46 to $53. Barclays analyst Adrienne Yih maintained an Overweight and raised the price target from $43 to $51. Wells Fargo analyst Ike Boruchow maintained an Equal-Weight and raised the price target from $40 to $48. URBN Price Action: Urban Outfitters shares closed Wednesday up 18.3% at $47.49, according to Benzinga Pro. Read Next: Boeing Faces Heat From ‘Frustrated’ Emirates Over $52 Billion Aircraft Delays Image Via Shutterstock. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Gov Alia appoints head of Benue agricultural company, two aides
SANTA CLARA, Calif. (AP) — Dan Campbell stood at the podium after Detroit blew a 17-point lead to San Francisco in last season's NFC title game and talked about how that might have been the Lions' only shot at reaching the Super Bowl. The coach knew how difficult it would be to maintain that high level of play through injuries, attrition and with a target on their back as a top contender in the NFC. Eleven months later as Campbell and the Lions prepare to return to Levi's Stadium for the first time since that loss , that has proved to be prophetic — for San Francisco instead of Detroit. The Lions (13-2) head into the rematch Monday night with the inside track at the top seed in the NFC playoffs, while the 49ers (6-9) have already been eliminated from postseason contention . The element of revenge for last season's 34-31 loss is secondary for Detroit, considering what's on the line the last two weeks of the season. The Lions can clinch the top seed in the NFC by winning their final two games or with a win against the Niners if Minnesota loses to Green Bay on Sunday. “Anytime we lose, the thought of losing is going to motivate you to not want to lose again, particularly with where you were at,” Campbell said. “So, that’s always going to bring its own level of motivation to it. But this is where we’re at in the season, we know that we need another win, we understand where we’re at in the division and the NFC, so I think it’s all encompassing.” While the Lions have no need to search for motivation, that's not the case for the 49ers, who are playing out the string of a lost season after making losing back-to-back NFC title games in 2021-22 and the Super Bowl last season. A run of injuries to key players like Christian McCaffrey, Trent Williams, Nick Bosa and Brandon Aiyuk, combined with inconsistent play all season have led to the 49ers having nothing to play for in the final two games. “It’s obviously not where you want to be this time of year,” Bosa said. "It’s different, especially watching where we’re at last year against this team. Just that feeling of December, January football is a feeling that I’ve gotten used to being really competitive and being in the mix. I think we’re doing a good job of staying engaged and obviously this is our job, so we’re going to finish it strong. Go ing deep Detroit’s faith in Jameson Williams is paying off, taking advantage of his game-breaking abilities with big plays. Jared Goff heaved an 82-yard touchdown pass over Williams’ shoulders and into his hands in last week’s win at Chicago. Earlier this season, Goff threw 70-, 64- and 52-yard passes for scores to the third-year receiver. “We work on it a ton, him and I do, and it’s a testament to him,” Goff said. “He’s asking for it. He wants that work, and I’m more than happy to give it to him during the week. It’s good. Our connection continues to grow. He’s obviously one of the best deep threats in our league, even when it’s not perfect.” Makeshift line The 49ers head into the game scrambling to put together an offensive line. Williams has been out for more than a month with an ankle injury and his backup at left tackle, Jaylon Moore, is now sidelined by a quadriceps injury. Left guard Aaron Banks injured his knee last week, while his backup Ben Bartch is already out with an ankle injury. That will leave the Niners with two third-stringers protecting Brock Purdy. But Shanahan said he isn’t thinking of sitting Purdy to protect him. “People deal with that throughout the year on other weeks, too,” he said. “I mean, we’ve got a football team. We’ve got to go out and we’ve got two games here and we’ve got to see what guys we can put out there and whatever we do we’re going to put a game plan together to, as best as we can to give us a chance to win.” Bag of tricks Lions offensive coordinator Ben Johnson, who may have a chance for the second straight offseason to be an NFL head coach, routinely pulls off trick plays and his latest was a doozy. Goff intentionally stumbled after taking a snap and Jahmyr Gibbs went to the ground as their teammates yelled, “fumble,” to fool the Bears on a 21-yard touchdown pass to Sam LaPorta. “Those make you feel good because everybody is invested in it,” Campbell said. “It’s fun. It’s different. It’s sound. “I know it sounds crazy, but it’s sound.” Just for kicks San Francisco kicker Jake Moody is having a rough second season after being drafted in the third round a year ago. Moody has missed seven field goals this season, including a 41-yarder last week at Miami. Moody is just 10 for 16 since coming back from a high ankle sprain in his kicking foot, but Shanahan said he still has confidence in him. “I still feel the same about him, that I believe he’ll be our guy,” Shanahan said. "I mean everyone’s got to perform and do things like that. I think he has had a tough year. Before his high ankle sprain, he missed one. ... I think he was 12 of 13 before that, so I thought he was doing really well." ___ AP Sports Writer Larry Lage contributed to this report. ___ AP NFL: https://apnews.com/hub/nfl Josh Dubow, The Associated PressDTE Energy Co. stock underperforms Wednesday when compared to competitors despite daily gainsPasithea Therapeutics ( NASDAQ:KTTA – Get Free Report ) and Daré Bioscience ( NASDAQ:DARE – Get Free Report ) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership. Volatility & Risk Pasithea Therapeutics has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Daré Bioscience has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Profitability This table compares Pasithea Therapeutics and Daré Bioscience’s net margins, return on equity and return on assets. Institutional and Insider Ownership Analyst Ratings This is a summary of recent recommendations and price targets for Pasithea Therapeutics and Daré Bioscience, as provided by MarketBeat.com. Daré Bioscience has a consensus price target of $24.00, indicating a potential upside of 618.56%. Given Daré Bioscience’s stronger consensus rating and higher possible upside, analysts clearly believe Daré Bioscience is more favorable than Pasithea Therapeutics. Earnings & Valuation This table compares Pasithea Therapeutics and Daré Bioscience”s revenue, earnings per share and valuation. Pasithea Therapeutics has higher earnings, but lower revenue than Daré Bioscience. Summary Daré Bioscience beats Pasithea Therapeutics on 7 of the 12 factors compared between the two stocks. About Pasithea Therapeutics ( Get Free Report ) Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida. About Daré Bioscience ( Get Free Report ) Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California. Receive News & Ratings for Pasithea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pasithea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .Kansas City Chiefs wide receiver Marquise "Hollywood" Brown, who has missed the entire regular season with a sternoclavicular joint dislocation suffered during an Aug. 10 preseason matchup , could potentially return to practice soon. "According to multiple sources, the Chiefs are optimistic that Brown will rejoin his teammates on the practice fields in mid-December," Nate Taylor of The Athletic reported. Brown signed a one-year, $7 million contract with the Chiefs this offseason. The 27-year-old caught 51 passes for 574 yards and four touchdowns in 14 games for the Arizona Cardinals last year. This article will be updated soon to provide more information and analysis. For more from Bleacher Report on this topic and from around the sports world, check out our B/R app , homepage and social feeds—including Twitter , Instagram , Facebook and TikTok .
Founded in 1899, CC Wakefield & Co. Limited initially focused on producing lubricants for trains and heavy machinery. Over time, the company expanded its expertise to develop specialized lubricants for automobiles and airplane engines, incorporating castor oil - a plant-based oil derived from castor beans - to ensure performance under extreme temperature conditions. The product was called Castrol, and the company was later renamed after its famous creation. 125 years later, remains at the forefront of innovation, applying its extensive expertise in fluid engineering to address modern challenges. One of its key focus areas is the development of advanced dielectric fluids for immersion cooling systems. This approach sees entire servers submerged in non-conductive fluids that absorb and transfer heat away from the components, eliminating the need for traditional fans. Advanced thermal management The Castrol ON Liquid Cooling Centre of Excellence in Pangbourne, UK, serves as a state-of-the-art research and development hub for liquid cooling technologies. The facility develops customized solutions and rigorously tests fluid dynamics, material compatibility, and server performance, to address the challenges of traditional cooling methods. In a recent visit, had the opportunity to see Castrol’s cutting-edge immersion tanks from providers like GRC and Submer and was impressed by the adaptability and efficiency of the solutions. Writer Jordan Ranous noted, “In one of the test cells, we observed GRC’s tank, which had a striking green glow due to the specific fluid Castrol was using. The servers submerged in this tank were undergoing compatibility and performance testing. Castrol ensures that every component, from CPUs to cables, can operate effectively in immersion cooling environments without degradation.” Castrol’s ON range of single-phase dielectric fluids, including DC15 and DC20, aims to deliver advanced thermal management, durability, and safety while maintaining efficient performance at operating temperatures between 40°C and 50°C, with some systems capable of handling up to 70°C. Chris Lockett, VP of Electrification and Castrol Product Innovation at BP, Castrol’s parent company, told , “At the moment, about 40% of power consumption in data centers goes toward cooling. Immersion cooling can drop that figure to less than 5%, significantly lowering power and water usage.” Data centers account for an estimated 2–3% of global power consumption, with current liquid cooling efforts primarily focused on direct-to-chip solutions. Immersion cooling has the potential to establish a new standard for thermal management and Castrol wants to lead this transformation, positioning itself as “a one-stop partner for the liquid cooling solutions of today and tomorrow.”Federal appeals court takes step closer to banning TikTok in US: Here's what to know
- Previous:
- Next: jollibee order online
